Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 5/20 | 0.45 |
| ▸ | CA2 | P00918 | 5/20 | 0.45 |
| ▸ | CA9 | Q16790 | 5/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6352330 | 0.85 | PTGS2 (1.00) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL6013929 | 0.83 | PTGS2 (0.80) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL6013909 | 0.81 | PTGS2 (0.93) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL6013908 | 0.80 | PTGS2 (0.71) | PTGS2PTGS1 | |
| SCHEMBL6013931 | 0.78 | PTGS2 (0.69) | PTGS2PTGS1 | |
| SCHEMBL6013912 | 0.74 | PTGS2 (0.72) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL5201734 | 0.74 | PTGS2 (0.66) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL8039356 | 0.71 | PTGS2 (0.70) | PTGS2 | |
| SCHEMBL8023423 | 0.68 | PTGS2 (0.68) | PTGS2PTGS1 | |
| SCHEMBL8641648 | 0.67 | PTGS2 (0.69) | PTGS2PTGS1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5466823-A | Antiinflammatory agents; FDA Orange book listed patent for Celebrex | G.D. SEARLE & CO. (US) | 1995-11-14 | — | — | US | claimed |
| US-20060167075-A1 | Modulators of FAAH | IRONWOOD PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167075-A1 | Modulators of FAAH | FAAH, FAAH2, HCRTR2 | PTGS2 107/4885PTGS1 73/4885CA1 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.